β2‐Adrenergic agonist as adjunct therapy to levodopa in Parkinson's disease

Abstract

We studied the effect of the β2-adrenergic agonist albuterol on Parkinson's disease (PD) patients receiving chronic levodopa treatment. The albuterol-treated patients demonstrated reduced parkinsonian symptoms and an increased ability to tap their index finger between two points 20 cm apart, and were able to perform a “walk test” in 70% of their control time. Three patients currently on chronic albuterol therapy still show amelioration of their parkinsonian symptoms, and two have reduced their daily levodopa dose. This study suggests that β2-adrenergic agonists as adjunct therapy to levodopa may be beneficial in PD.